Effects of doxazosin in patients with mild, intermediate, and severe benign prostatic hyperplasia

David F. Mobley, Norma Dias, Marcia Levenstein

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Traditionally, drug therapy for benign prostatic hyperplasia (BPH) has been reserved for patients with mild or moderate symptoms. The objective of this analysis was to compare responses to an alpha1-adrenergic receptor blocker, doxazosin, in patients with severe, intermediate, and mild disease. Data were analyzed from patients with symptomatic BPH who were enrolled in two 16-week, double-masked, placebo-controlled studies of doxazosin. In study 1, 163 hypertensive patients were stratified according to baseline maximum (Q(max)) and mean (Q(mean)) urinary flow rate as having severe, intermediate, or mild disease. In study 2, 82 normotensive patients were stratified according to their baseline American Urological Association (AUA) BPH symptom severity score and modified Boyarsky symptom bothersomeness score. Overall, doxazosin was significantly more effective than placebo in improving Q(max) and Q(mean) in study 1 and in improving the AUA-derived and modified Boyarsky scores in study 2. There were statistically significant differences in the response to treatment, as represented by Q(max), Q(mean), and modified Boyarsky score, between patients with severe, intermediate, and mild disease. There were no significant differences in the AUA-derived scores of patients in the three severity groups. These results have important clinical implications, suggesting that the majority of BPH patients are candidates for a course of drug therapy, regardless of baseline disease status.

Original languageEnglish (US)
Pages (from-to)101-109
Number of pages9
JournalClinical Therapeutics
Volume20
Issue number1
DOIs
StatePublished - Jan 1 1998

Keywords

  • Alpha-blocker
  • Benign prostatic hyperplasia
  • BPH
  • Doxazosin
  • Symptom score

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Effects of doxazosin in patients with mild, intermediate, and severe benign prostatic hyperplasia'. Together they form a unique fingerprint.

Cite this